How CAR-NK Cells Could Work Better than CAR-T Cells
James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
”The major hurdle addressed is donor cell rejection by the recipient’s immune system, which the authors determined is primarily mediated by host CD8+ T cells.
To overcome rejection, the researchers engineered a single gene construct that combines a selective shRNA to knock down rejection-related HLA Class I molecules, a Chimeric Antigen Receptor (CAR) for tumor targeting, and the expression of immune checkpoint ligands like PD-L1 or single-chain HLA-E (SCE).
This integrated approach not only enabled the CAR-NK cells to evade host-mediated rejection in mouse models but also surprisingly enhanced their anti-tumor activity and provided a favorable safety profile by reducing inflammatory cytokines.”
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
-
Mar 6, 2026, 14:56Women’s Health at the Center of the 2025–2027 Global Public Affairs Agenda – ISTH
-
Mar 6, 2026, 14:44Haroun Gajraj: A Must-Have Atlas for Venous Duplex and Phlebology
-
Mar 6, 2026, 14:35Selma Turkovic: Announcing the New Date for the WBIT Webinar
-
Mar 6, 2026, 14:33Caitlin Raymond: Why Transfusion Medicine Should Be Looped in Early in Transfusion Reactions
-
Mar 6, 2026, 14:28Peter Kouides: Why Raising the Ferritin Cutoff in Women Matters
-
Mar 6, 2026, 12:45Gajendra Singh Sandhu: Essential Brain Health Tips to Prevent Stroke
-
Mar 6, 2026, 12:41Jacqui McCallum: A Call to Action from the WSO 2025 Scientific Statement on Sex and Gender Differences in Stroke